Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$1.63MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Neal S. Walker
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Beta
- 0.80
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.04
Financials
Revenue
$1.63M+138.2%Net Income
$-21.50MEBITDA
$-21.30MFree Cash Flow
$-19.92MEPS (diluted)
$-0.15Shares Outstanding (diluted)
142.74M+566.5%Operating Expenses
$24.90MCash & Debt
$91.56MReturn of Capital
$0.00Revenue by Segment (annual)
$7.83MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.83M | $-64.92M | $-0.53 |
| 2024 | $18.72M | $-132.06M | $-1.71 |
| 2023 | $31.25M | $-88.48M | $-1.27 |
| 2022 | $29.75M | $-86.91M | $-1.33 |
| 2021 | $6.76M | $-90.86M | $-1.60 |
| 2020 | $6.48M | $-51.02M | $-1.20 |
| 2019 | $4.23M | $-161.35M | $-3.46 |
| 2018 | $10.09M | $-132.74M | $-4.03 |
| 2017 | $1.68M | $-68.52M | $-2.44 |
| 2016 | $0.00 | $-48.08M | $-2.25 |
| 2015 | $0.00 | $-20.56M | $-1.10 |
| 2014 | $0.00 | $-8.52M | $-0.80 |
| 2013 | $0.00 | $-5.24M | $-3.13 |
Valuation
ACRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (2)
- Newszacks.com·21d ago·Neutral
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock? Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
View source ↗ - Newszacks.com·56d ago·Positive
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.16 per share
Typical surprise +6.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.15 vs $-0.16beat
- Thu, May 7$-0.15 vs $-0.16beat
- Thu, Feb 26$-0.16 vs $-0.15miss
- Thu, Nov 6$-0.12 vs $-0.13beat
- Thu, Aug 7$-0.13 vs $-0.13beat
- Thu, May 8$-0.12 vs $-0.17beat
Estimates and results for ACRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACRS officers and directors.
- Bought
- —
- Sold
- $1.4m
0 trades
1 trade
- Leonard Braden Michaelsold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACRS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.